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Abstract 
The recent demonstration of the anti-oxidant properties of the Bcl-2 gene product suggested that expression of Bcl-2 may interfere with the nuclear 
migration of the NF-KB transcription factor, which is thought to depend on the presence of reactive oxygen intermediates. In mouse L cells, 
overexpression of B&2 interfered with the activation of NF-KB by H,O,. However, B&2 had no effect on the activation of NF-cB by TNF, even 
though it protected cells from TNF-induced apoptosis. The effects of exogenous pyrrolidine dithiocarbamate were very similar to those of B&2 
overexpression. We conclude that the protective ffects of anti-oxidants against induced apoptotic cell death are unrelated to their ability to interfere 
with NF-KB activation. 
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1. Introduction 
The bcl-2 proto-oncogene was initially defined as lying 
near one of the breakpoints of the t(14;18)(q32;q21) 
chromosomal translocations characteristic of follicular 
lymphomas. It was subsequently shown to be overex- 
pressed in these cells, having come under the control of 
regulatory elements in the IGH locus at 14q32. The Bcl-2 
gene product has recently received much attention be- 
cause it interferes with endogenously programmed or 
externally induced cell death which proceeds along the 
apoptotic pathway [ 1,2]. The oncogenic potential of the 
Bcl-2 protein lies in its ability to promote the survival of 
cell populations that would otherwise be programmed to 
die off, and thus bcl-2 has become the prototype of a 
newly defined class of oncogenes which act in a direction 
opposite to tumor suppressers such as p53 [224]. 
The mode of action of Bcl-2 has remained unclear 
until quite recently. The demonstration of its association 
with the outer mitochondrial membrane [5-71, at least in 
some cell types, has fueled speculations about its poten- 
tial implication in regulating respiratory processes. How- 
ever, cells lacking mitochondria are still protected by 
Bcl-2 expression [8], and C-terminal truncations of the 
protein which prevent its association with intracellular 
membranes do not necessarily reduce its protective ef- 
fects [5,9]. Important clues as to the physiological role of 
Bcl-2 have come from experiments demonstrating that it 
functions as an anti-oxidant, and interferes with cell 
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damage induced by reactive oxygen intermediates (ROI), 
by reducing the production of ROI, by protecting cells 
from their toxic effects, or perhaps by both mechanisms 
[lo, 111. The association of Bcl-2 with mitochondrial, nu- 
clear or endoplasmic reticular membranes [6,7] may then 
be explained by the fact that these are preferential sites 
of intracellular ROI-induced damage. 
The cytotoxic effects of the pleiotropic pro-inflamma- 
tory cytokine, tumor necrosis factor (TNF), are due in 
part to its ability to induce the generation of ROI [ 121. 
Overexpression of Mn-SOD has been shown to be a 
major pathway by which cells can protect themselves 
against the cytotoxic effects of TNF [13,14]. Consistent 
with this observation, overexpression of Bcl-2 has also 
been shown to protect cells against TNF-mediated cyto- 
toxicity [15-l 71. One of the most prominent early events 
induced by TNF in its target cells is an induction of the 
nuclear migration of the transcription factor NF-KB [ 18- 
201, which in turn induces the transcription of a large 
number of genes which participate in the inflammatory 
response [21]. Several studies have indicated that the 
generation of ROI may be an important step in the acti- 
vation of NF-lcB, presumably by inducing the prote- 
olytic degradation of IKB family proteins [22]. Specifi- 
cally, induction of nuclear NF-rcB is inhibited by 
anti-oxidants and iron chelators [23,24], and by drugs 
that block ROI generation by the respiratory chain [12]. 
However, there is also evidence indicating that there are 
pathways of NF-KB activation which may be independ- 
ent of ROI generation; in particular, TNF has been 
shown to induce NF-KB in a T lymphocyte line through 
a cascade of phospholipase activations in which ROIs do 
not seem to play a role [19]. The aim of this study was 
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to test whether Bcl-2 protects cells from the cytolytic 
activity of TNF by interfering with the ROI-dependent 
activation of NF-KB. 
2. Materials and methods 
2. I. Chemicals 
Pyrrolidine dithiocarbamate (PDTC), and protease inhibitors (see 
below) were purchased from Sigma Chemical Co. (Buchs, Switzerland). 
Recombinant human TNF was from Boehringer-Ingelheim (Ingelheim, 
Germany). Radioactively labeled compounds were from NEN DuPont 
(Regensdorf, Switzerland). Enzymes were purchased from Boehringer- 
Mannheim (Mannheim, Germany). 
2.2. Cell &es 
L929 cells were transformed by exposing them to supernatants from 
~2 cells transfected with pMV12 retroviral vector DNA, or with 
pMV12 containing either wild-type Bcl-2 or a C-terminal truncation 
(T3.1) which prevents Bcl-2 association with intracellular membranes. 
The Bcl-2 wt and Bcl-2 T3.1 L929 lines both strongly overexpress B&2, 
in either a predominantly membrane-associated (Bcl-2 wt) or cytosolic 
form (Bcl-2 T3.1). These Bcl-2 expressing lines have been characterized 
in detail earlier [9]. 
2.3. Gel mobility shift assays 
As a probe for NF-KB-like DNA binding activity, we used a double- 
stranded oligonucleotide derived from the rcB enhancer of the mouse 
K light chain locus (5’-GATCCGGAAAGTCCCCTGATC-3’), labeled 
at its 5’ ends with “P using T4 polynucleotide kinase. Nuclear extracts 
were prepared by lysing cells on ice in 10 mM HEPES (pH 7.9), 10 mM 
KCI, 0.1 mM EDTA, 0.1 mM EGTA with 0.5% NP-40, collecting the 
nuclei by spinning at 800 x g for 5 min, and extracting proteins from 
the nuclear pellet with 20 mM HEPES (pH 7.9) 400 mM KC], 1 mM 
EDTA, 1 mM EGTA, 1 mM DTT, supplemented with protease inhib- 
itors (1 mM PMSF, 200 t&ml chymostatin, 5@ml leupeptin, IO&ml 
antipain, 10 &ml protinin, 5 pglml pepstatin, 0.4 ,uM benzamidine). 
Extracts were adjusted to 1 mg/ml protein with the same buffer, and 
2 pg (2 ~1) was mixed on ice with 15 fmol probe and incubated for 30 
min before separation in an 8% acrylamide gel in 0.25 x TBE. The 
amount of probe trapped in a DNA/protein complex was quantitated 
by exposing the dried gel to a Phosphorimager plate (Molecular Dy- 
namics). 
3. Results and discussion 
In a 16-h survival assay, both Bcl-2-overexpressing 
L929 lines were significantly more resistant o the cyto- 
toxic action of TNF than the vector-transfected line (Fig. 
1). The protective effect of Bcl-2 could be mimicked by 
the addition of pyrrolidine dithiocarbamate (PDTC), a 
metal chelator which inhibits ROI generation by interfer- 
ing with the Fenton reaction which converts H,Oz to 
OH’ radicals (Fig. 1); exposing L929 cells overnight to 
100 PM PDTC alone had no marked effect on their 
survival (data not shown). These data suggest that in this 
experimental system, TNF cytotoxicity is an ROI-de- 
pendent event, as has been shown in many other cases 
[25]. The fact that both Bcl-2 and PDTC protect from 
TNF cytotoxicity is consistent with the notion that the 
effect of Bcl-2 on cell survival is mediated at least in part 
by its ability to detoxify ROI or interfere with their gen- 
eration. 
We measured the nuclear localization of NF-KB by 
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Fig. 1. Protection from TNF-mediated cell death by Bcl-2 and PDTC. 
L929 cells transfected with the pMV19 retroviral vector or with pMV19 
containing wt Bcl-2 or the T3.1 C-Terminal truncated Bcl-2 were cul- 
tured for 16 h in medium alone, or medium containing 3 ng/ml TNF, 
or (for the vector-transfected cells) medium containing 3 rig/ml TNF 
and 100 ,uM PDTC. Cell death was assessed after 16 h by uptake of 
Trypan blue. 
preparing nuclear extracts from these L929-derived lines 
after exposure to TNF and subjecting them to gel retar- 
dation assays. Surprisingly, early induction of NF-rcB by 
TNF was equivalent in the three cell lines, independently 
of Bcl-2 expression and even at limiting TNF concentra- 
tions (Fig. 2A; and data not shown). This suggested that 
TNF-mediated NF-KB induction may be an ROI-inde- 
pendent event, at least under our experimental condi- 
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Fig. 2. Lack of effect of antioxidants on activation of NF-lcB. L929 cells 
were exposed for 30 min to medium alone or medium containing 1.5 
&ml TNF. Nuclear extracts were prepared and gel retardation assays 
were performed as described in section 2. (A) Comparison of the vector- 
transfected line with the lines containing the Bcl-2 wt and or the Bcl-2 
T3.1 mutant. (B) PDTC was added to the vector-transfected line at the 
indicated concentrations 30 min before addition of TNF. 
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Fig. 3. Effects of B&2 and PDTC on H,O,-mediated activation of NF-KB. Nuclear NF-KB activity 2 h after a 30 min exposure to H,Oz (in PBS) 
was measured by gel retardation assays as above, and the amount of protein-bound oligonucleotide was quantitated by exposing the dried gel to 
a phosphorimager plate. (A) Effect of increasing H,O, concentrations on NF-lcB activation in vector- or Bcl-2 T3.1-transfected L929 cells. (B) Effect 
of PDTC on vector-transfected cells activated by 0.4 or 0.8 mM H,O, 
tions. Consistent with this hypothesis, PDTC failed to 
inhibit rapid NF-rcB activation by TNF (measured at 30 
min), even at concentrations well above those required 
to interfere efficiently with ROI generation (Fig. 2B). It 
should be noted that these results are at variance with 
those published by Schreck et al. [23,24]; the difference 
may lie in the fact that these authors measured NF-lcB 
activity 2 h after exposure to TNF, a time at which 
PDTC did also have an inhibitory effect in our experi- 
ments (see below). 
Since it has been reported that ROI can themselves 
induce the nuclear migration of NF-FOB, we tested the 
effects of H,Oz in our system. Indeed, H,O:, efficiently 
induced NF-FOB in the vector-transfected cell lines, but 
had very little effect in the Bcl-2 transfectants (Fig. 3A). 
Interestingly, the kinetics of NF-FOB induction by H,O1 
were slower than when TNF was used as the inducing 
agent, as nuclear NF-KB peaked at about 2 h instead of 
30 min (data not shown). In the vector-transfected cells, 
PDTC interfered with the activation of NF-lcB induced 
by H202, as expected (Fig. 3B). The data presented in 
Fig. 3 clearly show that ROI-induced NF-rcB can be 
observed in our system, and that its induction is inhibited 
by both endogenous Bcl-2 and exogenous PDTC. They 
also establish the fact that Bcl-2 can interfere not only 
with ROI-induced damage, but also with physiological 
processes (i.e. NF-lcB activation) induced by ROI. 
Induction of NF-kB by TNF has been reported to 
occur in two waves, the first of which is independent of 
PKC activity and occurs within 30 min of exposure to the 
ligand, while the second reaches a peak at about 3 h and 
is dependent on PKC activity [26]. The kinetics of NF-rcB 
induction by H,O, suggested that ROI may only be effec- 
tive in inducing the second wave. Accordingly, we tested 
whether expression of Bcl-2 or exogenous PDTC would 
influence the kinetics of appearance and disappearance 
of NF-FIB in the nucleus. As shown in Fig. 4, PDTC 
caused TNF-induced nuclear NF-FOB activity to decay 
much more rapidly than it did in control cells: at 4 h 
post-exposure to TNF, PDTC-treated cells had no resid- 
ual nuclear NF-KB, while control cells still contained 
about 50% of the 30 min peak value. Surprisingly, Bcl-2 
expression had no demonstrable ffect on NF-KB activa- 
tion kinetics, in spite of its effect as an anti-oxidant in 
other experimental situations. 
Our results indicate that the hypothesis of a tight inter- 
connection between ROI generation, NF-KB activation, 
and eventual cell death, is at the very least oversimpli- 
fied. The evidence for a role of ROI in programmed or 
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Fig. 4. Kinetics of NF-xB activation in the presence of antioxidants. 
Vector-transfected or Bcl-2 (wt or T3.1) transfected L929 cells were 
exposed to TNF (3 @ml) and nuclear NF-KB activity was measured 
at various times thereafter and quantitated as in Fig. 3. PDTC (400pM) 
was added 30 min before induction by TNF. 
48 
TNF-induced apoptotic cell death is very strong indeed 
[25], and entirely consistent with the data presented here. 
However, the rapid induction of NF-KB which follows 
exposure to TNF does not seem to be linked to the 
generation of ROI, as it is not blocked by anti-oxidants 
or by Bcl-2. It is definitely not sufficient for the induction 
of a full apoptotic response. It is possible, however, that 
the NF-KB which appears early after exposure to TNF 
is necessary for the induction of genes whose expression 
will lead to the generation of ROI. Paradoxically, the 
prolonged NF-KB response induced by TNF was 
strongly inhibited by PDTC, but not by Bcl-2. This 
points to a difference between the modes of action of 
these two compounds, whose effects are otherwise rather 
similar. One possible explanation is that Bcl-2, while 
inhibiting the ROI-mediated reactions which eventually 
lead to cell death, cannot interfere with the induction of 
NF-KB by endogenously generated ROI, whose appear- 
ance is prevented by PDTC. Alternatively, PDTC could 
be interfering with a metal-requiring reaction unrelated 
to the generation of ROI. Anyway, the lack of an effect 
of Bcl-2 on the late phase of TNF-induced NF-KB activa- 
tion excludes the possibility that this late phase can in 
itself trigger apoptotic cell death. 
In summary, we have shown that although anti-oxi- 
dants have been reported to interfere with both NF-KB 
activation and apoptotic cell death, these two effects are 
not causally related. Moreover, we could not demon- 
strate any quantitative or qualitative effects of Bcl-2 ex- 
pression on TNF-induced NF-lcB activation, although 
Bcl-2 did interfere with H,O,-induced activation. 
Acknowledgments: This work was supported in part by the Swiss Na- 
tional Science Fund. C.V.J. was a fellow of the Prof. Dr. Max Cloetta 
Foundation. We thank Chantal Mattmann and Nicolas Jury for excel- 
lent technical support and useful discussions. 
References 
[I] Reed, J.C. (1994) J. Cell Biol. 124, l-6. 
[2] Korsmeyer, S.J. (1992) Blood 80, 8799886. 
[3] Wang, Y., Szekely, L., Okan, I., Klein, G. and Wiman, K.G. 
(1993) Oncogene 8, 3427-343 1. 
[4] Reed, J.C. and Tanaka, S. (1993) Leuk. Lymphoma IO, 157-163. 
H. Albrecht et al. IFEBS Letters 351 (lYY4) 45 48 
[5] Nguyen, M., Millar, D.G., Yong, V.W., Korsmeyer, S.J. and 
Shore, G.C. (1993) J. Biol. Chem. 268, 25265-25268. 
[6] Nakai, M., Takeda, A., Cleary, M.L. and Endo, T. (1993) Bio- 
them. Biophys. Res. Commun. 196, 2333239. 
t71 
PI 
191 
IlO1 
[111 
[I21 
[I31 
t141 
(151 
[I61 
[I71 
USI 
1191 
WI 
1211 
t221 
~231 
~241 
1251 
WI 
Krajewski, S., Tanaka, S., Takayama, S., Schibler, M.J., Fenton, 
W. and Reed, J.C. (1993) Cancer Res. 53, 47014714. 
Jacobson, M.D., Burne, J.F., King, M.P., Miyashita, T., Reed, 
J.C. and Raff, M.C. (1993) Nature 361, 365-369. 
Bomer, C., Martinou, I., Irmler, M., Schaerer, E., Mattman, C., 
Martinou, J.-C. and Tschopp, J. (1994) J. Cell Biol. (in press). 
Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L. and 
Korsmeyer, S.J. (1993) Cell 75, 241-251. 
Kane, D.J., Sarafian, T.A., Anton, R., Hahn, H., Gralla, E.B., 
Valentine, J.S., Ord, T. and Bredesen, D.E. (1993) Science 262, 
12741277. 
Schulze-Osthoff, K., Beyaert, R., Vandevoorde, V., Haegeman, G. 
and Fiers, W. (1993) EMBO J. 12, 309553104. 
Wong, G.H., Elwell, J.H., Oberley, L.W. and Goeddel, D.V. 
(1989) Cell 58, 923-931. 
Wong, G.H. and Goeddel, D.V. (1988) Science 242, 941-944. 
Vanhaesebroeck, B., Reed, J.C., De Valck, D., Grooten, J., 
Miyashita, T., Tanaka, S., Beyaert, R., Van Roy, F. and Fiers, W. 
(1993) Oncogene 8, 1075-1081. 
Itoh, N., Tsujimoto, Y. and Nagata, S. (1993) J. Immunol. 151, 
621-627. 
Hennet, T., Bertoni, G., Richter, C. and Peterhans, E. (1993) 
Cancer Res. 53, 14561460. 
Hohmann, H.P., Remy, R., Poschl, B. and van Loon, A.P. (1990) 
J. Biol. Chem. 265, 15183315188. 
Schiitze, S., Potthoff, K., Machleidt, T., Berkovic, D., Wiegmann, 
K. and Kronke, M. (1992) Cell 71, 7655776. 
Hohmann, H.P., Remy, R., Scheidereit, C. and van Loon, A.P. 
(1991) Mol. Cell. Biol. II, 259-266. 
Lenardo, M.J. and Baltimore, D. (1989) Cell 58, 227-229. 
Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben Neriah, 
Y. and Baeuerle, P. (1993) Nature 365, 182-185. 
Schreck, R., Rieber, P. and Baeuerle, P.A. (1991) EMBO J. 10, 
2247-2258. 
Schreck, R., Meier, B., Mannel, D.N., Droge, W. and Baeuerle, 
P.A. (1992) J. Exp. Med. 175, 1181-1194. 
Buttke, T.M. and Sandstrom, P.A. (1994) Immunol. Today 15, 
7710. 
Hohmann, H.P., Remy, R., Aigner, L., Brockhaus, M. and van 
Loon, A.P. (1992) J. Biol. Chem. 267, 206552072. 
